amivantamab

1. 15:30
   The Lancet

   [评论] EGFR-TKI治疗后EGFR突变非小细胞肺癌的多种标准治疗：进展、碎片化还是必然性？

   该评论审视EGFR-TKI治疗后EGFR突变非小细胞肺癌多种标准治疗的进展、碎片化与必然性。全球MARIPOSA-2试验显示，amivantamab联合铂类-pemetrexed化疗较单用铂类-pemetrexed化疗改善osimertinib治疗后进展患者的PFS，并成为NCCN和ESMO首选二线方案。

1. 22:50
   ESMO 2026 现场信号

   Exciting emerging data in 1L R/M #HNSCC at #ESMO26!
2. 17:34
   ESMO 2026 现场信号

   At #ESMO26 we spoke with Ari Rosenberg (@UCCancerCenter) who discussed emerging strategies for recurrent/metastatic head and neck cancer, including the frontline carboplatin-amivan

1. 14:57
   ESMO 2026 现场信号

   🦋 Making amivantamab + lazertinib safer: new COCOON data at #ESMO26!
2. 14:52
   ESMO 2026 现场信号

   We may be starting a fire only to try putting it out with a water gun.
3. 14:51
   ESMO 2026 现场信号

   Simplified dermatological Amivantamab strategy; lazertinib 1 cycle lead in lazer then fortnightly Amivantamab….. this seems to be they way to go; interestingly UK cancer drugs fund
4. 14:51
   ESMO 2026 现场信号

   #ESMO26 Dr. Byoung Cho @cbcbc1971 shows simplified dermatologic prophylaxis in COCOON with 1L SC amivantamab + lazertinib for EGFR+ NSCLC had reduction in dermatologic AEs similar

当前热度 30·可比范围峰值 40（10月24日 15:00）·近 24 小时可比范围变化 +60%·当前参与者 7

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。